Phase II Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine

The Quick Take
HONG KONG, Nov. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific antibody ivonescimab in the perioperative treatment of resectable non-small cell lung cancer (NSCLC) have been...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
Update zur Geschäftsentwicklung in den ersten neun Monaten 2026
Strategische Fortschritte erzielen und Wachstumsaussichten stärken ATHEN, Griechenland und LONDON, 6. November 2026 /PRNewswire/ -- METLEN Energy & Metals PLC…
Local
Firefighters rescue cat from burning home in south Las Vegas valley - KSNV
Firefighters rescue cat from burning home in south Las Vegas valley KSNV
Business
Chewy chief accounting officer sells $110,745 in stock
Business
